Market closed

NovoCure/$NVCR

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About NovoCure

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

Ticker

$NVCR

Sector

Health Care

Trading on

NASDAQ

Industry

Health Care Equipment & Supplies

Headquarters

Saint Helier, Jersey

Employees

1,453

Website

www.novocure.com

NovoCure Metrics

BasicAdvanced

$3B

-

-$1.39

0.70 -

Price and volume

Market cap

$3B

Beta

0.7

52-week high

$34.13

52-week low

$11.70

Average daily volume

1.6M

Financial strength

Current ratio

1.49

Quick ratio

1.432

Long term debt to equity

32.788

Total debt to equity

187.268

Interest coverage (TTM)

-17.55%

Management effectiveness

Return on assets (TTM)

-7.93%

Return on equity (TTM)

-39.70%

Valuation

Price to revenue (TTM)

5.093

Price to book

8.2

Price to tangible book (TTM)

8.2

Price to free cash flow (TTM)

-37.622

Growth

Revenue change (TTM)

14.63%

Earnings per share change (TTM)

-25.18%

3-year revenue growth (CAGR)

1.92%

3-year earnings per share growth (CAGR)

73.31%

What the Analysts think about NovoCure

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for NovoCure stock.

NovoCure Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

NovoCure Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

NovoCure News

AllArticlesVideos

Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference

Business Wire·2 weeks ago

NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer

Seeking Alpha·1 month ago

Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields

Seeking Alpha·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVCR

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for NovoCure stock?

NovoCure (NVCR) has a market cap of $3B as of January 15, 2025.

What is the P/E ratio for NovoCure stock?

The price to earnings (P/E) ratio for NovoCure (NVCR) stock is 0 as of January 15, 2025.

Does NovoCure stock pay dividends?

No, NovoCure (NVCR) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next NovoCure dividend payment date?

NovoCure (NVCR) stock does not pay dividends to its shareholders.

What is the beta indicator for NovoCure?

NovoCure (NVCR) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.